Researchers worldwide are working around the clock to find a vaccine against COVID-19. With several promising candidates on the horizon, plans for the distribution and use of the vaccines must be considered. Join WSPID for 2 presentations and a Q&A on the different COVID-19 vaccine platforms and an overview of current vaccine rollout plans.
The session includes talks by Walter Orenstein, Associate Director of the Emory Vaccine Center and former Director of the US Immunization Program and by Miguel O'Ryan, Full Professor, Faculty of Medicine at the University of Chile and member of the COVID-19 Vaccine Committee at the Ministry of Science, Chile.
Date: 9 December 2020
Time: 10.00-11.30AM EST | 4.00-5.30PM CET
To register visit: https://wspid.org/
Read moreTDR, in partnership with the WHO Global Tuberculosis Programme (GTB), has developed an interactive web-based toolkit that supports national TB programmes and other partners to conduct implementation research designed to evaluate digital technologies for TB care. This is being launched today at a workshop taking place in Beijing, China.
“The WHO Global TB Programme and TDR are helping countries to collect evidence on innovative digital technologies to improve TB prevention and care,” said Tereza Kasaeva, Director of the WHO Global TB Programme. “The toolkit and the training course will help countries to mount more effective interventions and to contribute to global policy at this critical juncture when TB practitioners face the added challenge of COVID-19.”
For more information visit https://www.who.int/tdr/news/2020/WHO-TDR-Fact-Sheet-IR-Toolkit.pdf
Read moreCurrently very little is known about the clinical, biological, psychological and socioenvironmental impact of Coronavirus Disease 2019 (COVID-19). While most people have uncomplicated recoveries, some continue to live with prolonged illness and symptoms. The most common of these are fatigue, breathing difficulties, joint pain and chest pain. In those whose symptoms persist, COVID-19 has been associated with a worsened quality of life for almost half of them. These on-going difficulties affect not only patients who were hospitalised but also those with mild COVID-19 who were not hospitalised.
There is an urgent need for robust scientific studies into the long-term impact of COVID-19. An understanding of the breadth of the physical, psychological and social complications must be developed and any specific risk factors for developing Long COVID, and also the populations at risk, must be identified. Hospital management teams must be informed to support prevention, rehabilitation and interventions to improve recovery and patient outcomes.
For more details and to register please visit https://cconline.eventsair.com/isaric-long-covid-19-forum/register/Site/Register
INGSA is excited to announce an opportunity for researchers and policy-professionals in Low and Middle Income countries, who would like to undertake projects looking at how evidence was used in the COVID-19 response.
INGSA is providing six x €8000 grants for deep-dive case studies on evidence-to-policy pathways at a local, national or regional level.
Grants will be awarded to both science researchers as well as policy professionals so we encourage everyone to apply.
This is a quick turn around grant program so applications will close on the 29th November.
For all the information on eligible countries and grant requirements see: https://www.ingsa.org/grant-programme/2021-knowledge-associates/